Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391961 · ClinicalTrials.gov registry record · Phase 2
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02391961: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT02391961 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02391961, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases. Fatigue interferes with everyday functioning but, unfortunately, little is known about its mechanisms. The investigators propose a characteristic eye movement abnormality (internuclear ophthalmoparesis, INO), commonly encountered in MS, as a simple model for primary motor fatigue. The investigators described worsening of ocular performance in MS patients with INO following visual tasks (ocular motor fatigue), which is likely due to decreased neural conduction along brain pathways injured by MS. This mechanism could represent a major component of MS-related primary motor fatigue. Relevant to Veterans' care, INO is a significant cause of visual disability, especially when complicated by ocular fatigue, and limits daily activities such as reading and driving. The investigators propose a medical treatment to improve ocular performance/fatigue in INO, which can reduce visual disability and improve quality of life in Veterans with MS.
Interventions
- DRUG Placebo
- DRUG Dalfampridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2019-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02391961
The ClinicalTrials.gov registry entry for NCT02391961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02391961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02391961 about?
NCT02391961 is a clinical study titled "Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis". Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases. Fatigue interferes with everyday functioning but, unfortunately, little is known about its mechanisms. The investigators propose a characteristic eye movement abnorm...
What is the current status of trial NCT02391961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-04-01. Estimated completion is 2019-03-31.
What interventions are being tested in trial NCT02391961?
The interventions under investigation include: Placebo (DRUG), Dalfampridine (DRUG).
Who is sponsoring clinical trial NCT02391961?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.